Evidence map›Paper›PMID 40703713›Full record

ArticleBiotechnologia2025

Search continues: Exploring immunoinformatics platforms for designing an effective multiepitope malaria vaccine candidate.

Charles Osuji, Godwin Etuk-Udo

Abstract read
In one paragraph

Article in Biotechnologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Charles OsujiBiotechnology Advanced Research Center, Sheda Science and Technology Complex, Abuja, Nigeria.
Godwin Etuk-UdoBiotechnology Advanced Research Center, Sheda Science and Technology Complex, Abuja, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The prevailing public health threat posed by malaria, especially in developing countries, remains a serious concern despite the availability of preventive and control measures. While vaccination offers a powerful means of combating malaria, it has not been fully exploited due to previous unsuccessful attempts before the launch of the RTS,S vaccine. A major challenge in malaria vaccine development continues to be the identification of effective targets capable of eliciting robust immunity, given the complexity of the parasites' life cycle. Leveraging on the breakthrough of the newly approved malaria vaccine, efforts to develop more effective prophylactic solutions continue with renewed determination. Materials and methods: In this study, a standard structural bioinformatics pipeline was employed to design a multiepitope subunit vaccine against Results: Out of an initial pool of 133 epitopes, 30 vaccine-fit epitopes were selected, resulting in a final vaccine construct comprising 570 amino acid residues. This included 12 linear B-cells, 11 cytotoxic T-lymphocytes, and 7 helper T-lymphocyte epitopes, all with favorable predicted structural, antigenic, and physicochemical properties. The construct also demonstrated strong global population coverage (95.04%), robust molecular binding, and simulated immune responses. Conclusions: With the evolving "Omics" technologies through reverse vaccinology, discovering and designing promising vaccine candidates becomes easier without many challenging experimental rigors. This study highlights the potential of immunoinformatics-aided approaches in accelerating effective malaria vaccine development.

Indexed as

epitopesimmunoinformaticsmalariaPlasmodium falciparumvaccine

Identifiers

PMID40703713
PMCPMC12281499

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.